Adult dengue vaccination in a low transmission setting: A modelling study in Singapore
Fig 5
Impact of vaccination on dengue cases and hospitalizations, with and without efficacy against infection.
Percentage of reported dengue cases averted by targeted age groups under (a) DENV-1, (b) DENV-2, (c) DENV-3, and (d) DENV-4 dominant scenarios, and percentage of hospitalizations due to dengue averted by targeted age groups under (e) DENV-1, (f) DENV-2, (g) DENV-3, and (h) DENV-4 dominant scenarios, assuming the vaccine has efficacy against infection with any serotype similar to that of Dengvaxia, over a 10-year routine vaccination program with 80% vaccine coverage. Bars represent mean model estimates, and error bars indicate the corresponding 95% range of simulations.